Avoro Capital Advisors LLC
Q2 2020 13F-HR Holdings
Net value change ($000)
+2,095,355
(70.7%)
New positions
8
Sold out positions
5
Turnover %
9.2%
Sector allocation + QoQ delta (equities-only)
Snapshot: Change Analysis
Compared to Q1 2020
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| IMMUNOMEDICS INC | 600,040 | 181.7% |
| Horizon Therapeutics Public Ltd Co | 197,968 | 146.1% |
| Mirati Therapeutics, Inc. | 173,277 | 54.8% |
| Mersana Therapeutics, Inc. | 152,100 | NEW |
| MyoKardia, Inc. | 114,373 | 170.0% |
| SRPT | 113,525 | 73.2% |
| ADAPY | 100,100 | NEW |
| ARGX | 95,108 | 77.1% |
| ADVM | 88,519 | 126.7% |
| BMRN | 65,094 | 39.9% |
Top Reduces (Value $000, Stocks/ETFs)
| PTCT | -37,054 | -69.2% |
| Sage Therapeutics, Inc. | -28,720 | -100.0% |
| Tricida, Inc. | -13,542 | -45.1% |
| QURE | -10,703 | -13.7% |
| ZOGENIX, INC. | -8,471 | -12.2% |
| TGTX | -7,872 | -100.0% |
| AGEN | -6,738 | -100.0% |
| ImmunoGen, Inc. | -6,479 | -100.0% |
| ACAD | -6,126 | -100.0% |
| BIODELIVERY SCIENCES INTERNATIONAL INC | -2,498 | -22.0% |
Instrument mix + QoQ Δ (ex-options)
Derivatives reported exposure ($000):
70
(0.0% of total reported value)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|